Changchun High-tech announces that its controlling subsidiary, Jinsai Pharmaceutical, has received the “Acceptance Notice” issued by the National Medical Products Administration. The domestic clinical trial application for Jinsai Pharmaceutical’s GenSci161 injection has been accepted. GenSci161 injection is a Class 1 biological therapeutic drug independently developed by Jinsai Pharmaceutical, intended for the treatment of endometriosis and suppurative hidradenitis.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Changchun High-tech: Subsidiary GenSci161 Injection Drug Registration Clinical Trial Application Accepted
Changchun High-tech announces that its controlling subsidiary, Jinsai Pharmaceutical, has received the “Acceptance Notice” issued by the National Medical Products Administration. The domestic clinical trial application for Jinsai Pharmaceutical’s GenSci161 injection has been accepted. GenSci161 injection is a Class 1 biological therapeutic drug independently developed by Jinsai Pharmaceutical, intended for the treatment of endometriosis and suppurative hidradenitis.